Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system.

[1]  J. Blesa,et al.  Animal Models of Parkinson’s Disease , 2021, The Hidden Life of the Basal Ganglia.

[2]  Marios Politis,et al.  Neuroimaging in Parkinson disease: from research setting to clinical practice , 2014, Nature Reviews Neurology.

[3]  A. Nadjar,et al.  n-3 LCPUFA improves cognition: the young, the old and the sick. , 2014, Prostaglandins, leukotrienes, and essential fatty acids.

[4]  E. Morya,et al.  Omega-3 deficiency and neurodegeneration in the substantia nigra: involvement of increased nitric oxide production and reduced BDNF expression. , 2014, Biochimica et biophysica acta.

[5]  S. Cuzzocrea,et al.  Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies , 2014, Journal of Neuroinflammation.

[6]  A. Schapira,et al.  Therapeutic prospects for Parkinson disease , 2013, Annals of neurology.

[7]  E. Bézard,et al.  Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  C. W. Picanço-Diniz,et al.  Dopaminergic cell populations of the rat substantia nigra are differentially affected by essential fatty acid dietary restriction over two generations , 2012, Journal of Chemical Neuroanatomy.

[9]  D. Surmeier,et al.  Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease , 2012, Behavioural Brain Research.

[10]  S. Pluchino,et al.  Plasticity of Subventricular Zone Neuroprogenitors in MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Mouse Model of Parkinson's Disease Involves Cross Talk between Inflammatory and Wnt/β-Catenin Signaling Pathways: Functional Consequences for Neuroprotection and Repair , 2012, The Journal of Neuroscience.

[11]  F. Cicchetti,et al.  The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration , 2011, Journal of Neuroinflammation.

[12]  F. Calon,et al.  Accumulation of Dietary Docosahexaenoic Acid in the Brain Attenuates Acute Immune Response and Development of Postischemic Neuronal Damage , 2011, Stroke.

[13]  F. Cicchetti,et al.  Impact of omega-3 fatty acids in Parkinson's disease , 2011, Ageing Research Reviews.

[14]  F. Calon,et al.  Chronic dietary intake of α-linolenic acid does not replicate the effects of DHA on passive properties of entorhinal cortex neurons , 2011, British Journal of Nutrition.

[15]  C. Dixon,et al.  Oral fish oil restores striatal dopamine release after traumatic brain injury , 2011, Neuroscience Letters.

[16]  L. Mosconi,et al.  PET/CT in diagnosis of movement disorders , 2011, Annals of the New York Academy of Sciences.

[17]  E. Bézard,et al.  A tale on animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[18]  Paola Piccini,et al.  Priorities in Parkinson's disease research , 2011, Nature Reviews Drug Discovery.

[19]  F. Calon,et al.  DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice , 2011, PloS one.

[20]  F. Cicchetti,et al.  Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease , 2011, Journal of Lipid Research.

[21]  L. Robson,et al.  Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals , 2010, Neurobiology of Aging.

[22]  J. Anselmo-Franci,et al.  Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease , 2010, Neuroscience Research.

[23]  F. Cicchetti,et al.  Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  F. Cicchetti,et al.  Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions , 2009, Journal of neurochemistry.

[25]  J. Brotchie,et al.  Mechanisms compensating for dopamine loss in early Parkinson disease , 2009, Neurology.

[26]  F. Cicchetti,et al.  Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  S. Chalon.  Omega-3 fatty acids and monoamine neurotransmission. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  E. Bézard.  A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. , 2006, Behavioural pharmacology.

[29]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[30]  B. Davletov,et al.  Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3 , 2006, Nature.

[31]  A. Rajput,et al.  Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys , 2006, Neurochemistry International.

[32]  A. Sampson,et al.  Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.

[33]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[35]  D. Brooks.  Neuroimaging in Parkinson’s disease , 2004, NeuroRX.

[36]  O. Hornykiewicz,et al.  Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease , 2003, Neurobiology of Disease.

[37]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[38]  J. Schneider,et al.  GABA–opioid interactions in the globus pallidus: [D‐Ala2]‐Met‐enkephalinamide attenuates potassium‐evoked GABA release after nigrostriatal lesion , 2002, Journal of neurochemistry.

[39]  N. Salem,et al.  A Decrease in Cell Size Accompanies a Loss of Docosahexaenoate in the Rat Hippocampus , 2002, Nutritional neuroscience.

[40]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[41]  B Bioulac,et al.  Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[42]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[43]  P. Blanchet,et al.  Effect of MPTP‐induced denervation on basal ganglia GABAB receptors: Correlation with dopamine concentrations and dopamine transporter , 2001, Synapse.

[44]  A. Ho,et al.  Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease , 1998 .

[45]  Y. Mitsumoto,et al.  Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.

[46]  Y. Agid,et al.  Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[47]  J. Schneider,et al.  Spontaneous functional recovery from parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons , 1994, Brain Research Bulletin.

[48]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[49]  J. Schneider,et al.  Neurochemical evaluation of the striatum in symptomatic and recovered mptp-treated cats , 1991, Neuroscience.

[50]  I. Date,et al.  Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.

[51]  R. Roth,et al.  MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.

[52]  M. Lévesque,et al.  Cystamine / cysteamine rescue the dopaminergic system and show neurorestorative properties in an animal model of Parkinson ’ s disease , 2015 .

[53]  N. Bazan,et al.  The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[54]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[55]  Moussa B. H. Youdim,et al.  Neuroprotective Strategies in Parkinson’s Disease , 2003, CNS drugs.